Ann: PYC Therapeutics Investor Call - 18 August 2022, page-13

you can view it as an update on competitor landscape’s platform modality - validation or invalidation - PYC is first in class/best of the best

they were way ahead of us clinically - best of the best Ivy League / top tier US hospitals/labs - PYC has quite elegantly illustrated their strategic approach - we should be marked closer to the RNA leaders in terms of probability of success / de-risk to market… but unfortunately we have to wait until we prove the reality of the below table via VP-001 capability before the market will RE-rate us to 52 week highs like the rest of the US big boys.



Above scientific poster table is a Good one to save on your phone to go back to to see you through doubts that the dark cold SP winter can throw up